Wyss Institute
The Wyss Institute for Biologically Inspired Engineering at Harvard University develops bioinspired materials, organ-on-chip technology, diagnostics, and AI platforms to address healthcare and sustainability challenges, commercializing discoveries through licensing, spin-out startups, and pharmaceutical partnerships.
- Company typePrivate
- Founded2009
- HeadquartersBoston, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Wyss Institute does
The Wyss Institute for Biologically Inspired Engineering is a Harvard University research institute founded in 2009 with a $125 million donation from Hansjörg Wyss, headquartered at 201 Brookline Avenue in Boston. It develops biologically inspired materials and devices — including Human Organs-on-Chips (microfluidic devices lined with living human cells that mimic lung, intestine, kidney, and bone marrow function), the dSHERLOCK CRISPR-based diagnostic platform, Implantable Living Materials for on-demand drug delivery, RNA immunotherapeutics, and the AI DataHub for ML-driven drug discovery and biomarker development. Its work spans drug development, disease modeling, personalized medicine, infectious disease diagnostics, and environmental sustainability challenges.
The institute operates a hybrid translational model rather than a conventional product business. It is funded primarily through federal research grants (ARPA-H, DARPA, NIH, NASA — including $27M from ARPA-H in 2024 for RNA therapeutics and $25M in 2025 from the ARPA-H PRINT program for 3D bioprinting) and philanthropy, supplemented by direct pharmaceutical collaborations with AstraZeneca and Johnson & Johnson. It commercializes IP through startup spin-outs — Emulate (Organ Chips, launched 2014, $200M+ raised), Prapela (infant health vibrating mattress, 2018), Manifold Bio (protein barcoding, 2020, $40M Series A), Unravel Biosciences (AI drug discovery for rare diseases, 2021), Dyno Therapeutics (AAV engineering), and Cerulean Scientific (medical device coatings, ~$20M in NIH/CDMRP grants) — typically retaining minority stakes. Its 2022 contribution to the FDA Modernization Act 2.0 and integration with 12+ academic and hospital partners (including MIT, Brigham and Women's, MGH, Boston Children's, Charité Berlin, and University of Zurich) position it as a structurally embedded translation engine rather than a standalone commercial enterprise.
Wyss Institute firmographics
Firmographics- Name
- Wyss Institute
- Legal name
- Hansjörg Wyss Institute for Biologically Inspired Engineering at Harvard University
- Website
- https://wyss.harvard.edu
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- The Wyss Institute for Biologically Inspired Engineering at Harvard University develops bioinspired materials, organ-on-chip technology, diagnostics, and AI platforms to address healthcare and sustainability challenges, commercializing discoveries through licensing, spin-out startups, and pharmaceutical partnerships.
- Ownership category
- akta.pro rank
Wyss Institute industry classification
Industry- Product category
- Biomedical Research and Technology Licensing
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where Wyss Institute is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Wyss Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Others
Revenue model
- Technology Licensing: Licensing of patented technologies and IP to established companies for commercialization. Examples include licensing to Emulate, Prapela, Manifold Bio, and others.
- Startup Formation: Spin-out companies formed from Wyss research to commercialize specific technologies, such as Emulate (Organ Chips), Prapela (infant health devices), Manifold Bio (protein therapeutics), and others.
- Government Research Grants: Major funding from federal agencies including ARPA-H ($27M for RNA therapeutics), DARPA, NIH for various research programs and validation projects.
- Collaborative Research Agreements: Direct partnerships with pharmaceutical companies like AstraZeneca and Johnson & Johnson for drug development using Organ Chips and other technologies.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Wyss Institute product offering
Product offeringCore offering
The Wyss Institute develops biologically inspired materials, devices, and platform technologies for healthcare and sustainability. Core offerings include Human Organs-on-Chips (microfluidic devices mimicking human organ function), the AI DataHub (AI-integrated biological data platform for drug discovery), the Diagnostics for Human and Planetary Health Platform, CRISPR-based diagnostics (dSHERLOCK), protein barcoding platforms, and RNA immunotherapeutics. Technologies are commercialized through licensing agreements, startup formation, and collaborative research with pharmaceutical companies and government agencies.
Product overview
The Wyss Institute develops a portfolio of biologically inspired technologies primarily focused on healthcare applications. The core offerings include Human Organs-on-Chips (microfluidic devices for drug testing), the AI DataHub (for AI-accelerated drug discovery), and the Diagnostics for Human and Planetary Health Platform. These are complemented by spun-out startups including Emulate, Inc. (commercializing Organ Chips), Manifold Bio (protein therapeutic development), and Prapela (infant health devices). The institute also operates Translational AI Catalyst for cross-functional AI initiatives. The portfolio spans from early-stage research technologies like the Multiplexed Protein Binding and Barcoding Platform to validated products like the Active Mattress for Infant Health.
Differentiator
Problem solved
Functional benefit
Brands
- Human Organs-on-Chips: Microfluidic devices lined with living human cells for drug development, disease modeling, and personalized medicine
- Lumineers
- Translational AI Catalyst
- AI DataHub
- Diagnostics for Human and Planetary Health
- Wyss DxA
- Brain Targeting Program
- Reimagine the World
Products and services
- Human Organs-on-Chips Microfluidic devices lined with living human cells that recreate organ-level functions (lung, intestine, kidney, bone marrow, liver, brain) for drug testing, disease modeling, and personalized medicine. Licensed to Emulate, Inc. and installed in over 150 labs including 17 of the top 25 global biopharmaceutical companies.
- AI DataHub AI platform that integrates biological data and tissue models including Organ Chips, organoid cultures, and animal model datasets combined with machine learning and multi-omics capabilities to accelerate drug discovery and biomarker development.
- Diagnostics for Human and Planetary Health Platform
Quantifiable outcome
- Reduces drug development timelines from 10+ years to months
- +4 more outcomes
Companies that use Wyss Institute
Customer profileNamed customers5 records
Segments1 record
Ideal customer profiles3 records
Wyss Institute technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature8 records
Wyss Institute partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and flagship.
- Harvard Medical SchoolcoreWyss Institute is part of Harvard University's ecosystem, working closely with Harvard Medical School faculty and researchers on biological engineering innovations.
- MITcoreCollaboration with MIT on various research projects including Brain Targeting Program, AI-enabled drug discovery, and machine learning for antibiotic discovery.
- Brigham and Women's HospitalcoreClinical partner providing access to patient samples, clinical expertise, and collaboration on diagnostic and therapeutic development through the Brigham-Wyss DxA.
- Massachusetts General HospitalcoreClinical collaboration on various research projects including infectious disease therapeutics and diagnostics development.
- NASAcoreNASA AVATAR program using Organ Chips on Artemis II mission to study effects of deep space radiation on human health for astronaut safety.
- AstraZenecacoreStrategic collaboration using Organ Chips to better predict human response in drug development process.
- Johnson & JohnsoncoreStrategic collaboration using Organ Chips platform to better predict human response in drug development process.
- Broad InstitutecoreCollaboration on machine learning-driven antibiotic discovery research for drug-resistant gonorrhea.
- Tufts UniversitycoreAcademic partner collaborating on neurobot research and biological machines development.
- Boston UniversitycoreCollaboration on ESCAPE technique for 3D biofabrication of human tissue structures using gallium.
- Charité BerlincoreInternational academic partner in the Wyss consortium for biological engineering research.
- University of ZurichcoreInternational academic partner collaborating on various research initiatives including Wyss Zurich.
- Emulate, Inc.flagshipSpin-off company commercializing Human Organs-on-Chips technology. Launched in 2014, installed in 150+ labs including top pharma companies.
- PrapelacoreStartup commercializing vibrating mattress technology for infant health conditions including apnea and neonatal opioid withdrawal syndrome.
- Manifold BiocoreStartup commercializing multiplexed protein binding and barcoding platform for drug development, raised $5.4M seed and $40M Series A.
- Cerulean ScientificcoreMedical device startup developing implants and catheters using tethered liquid perfluorocarbon coating technology licensed from Wyss Institute.
- Cerulean ScientificcoreCerulean Scientific has raised nearly $20 million in grants from NIH and Congressionally Directed Medical Research Programs to develop coated medical devices.
- Unravel BiosciencescoreSpun out from Wyss Institute in 2021 to commercialize nemoCAD/BioNAV AI platform for drug discovery; received FDA Orphan Drug Designation for Rett syndrome treatment.
- Dyno TherapeuticscoreStartup commercializing AI-powered AAV capsid engineering technology for gene therapy delivery.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Wyss Institute competitors and assessment
Company assessmentEmerging players
- TissUse GmbH: Berlin-based organ-on-chip and multi-organ-chip developer with HUMIMIC platform. Comparable to Wyss/Emulate on Organ Chip product category and pharma customer base, with strength in European markets and toxicology applications.
Broad incumbents
- Gladstone Institutes: San Francisco-based nonprofit biomedical research institute affiliated with UCSF. Comparable academic-research-translation model to Wyss, focused on cardiovascular, neurological, and infectious disease research with spinout activity.
- Koch Institute for Integrative Cancer Research (MIT): MIT cancer research institute with similar model of translating bioengineering breakthroughs into commercial applications. Comparable in academic-industry translation framework and Boston/Cambridge location, though focused specifically on oncology.
- Howard Hughes Medical Institute (HHMI): Largest US biomedical research organization funding Investigator-led science with commercialization pathways. Comparable to Wyss as a large, well-funded biomedical research engine that supports faculty-driven discovery and translation.
Direct peers
- Emulate, Inc. Direct spinout commercializing Wyss's Human Organs-on-Chips technology. Installed in 150+ labs including 17 of top 25 biopharma and used by the FDA — the most direct commercial manifestation of the Wyss platform.
- Manifold Bio: Wyss spinout commercializing multiplexed protein binding and barcoding platform for protein therapeutic discovery. Raised $40M Series A; direct peer demonstrating the institute's protein-engineering capabilities and AI-augmented discovery thesis.
- Dyno Therapeutics: Wyss spinout commercializing AI-powered AAV capsid engineering for gene therapy delivery. Direct peer within the Wyss spinout portfolio and comparable AI-meets-biotech model; provides additional validation of the Wyss translation engine.
- CN Bio: Commercial competitor offering organ-on-chip and microphysiological systems for drug development. Closely comparable to Emulate in product category (Organ Chips) and target customer (top biopharma), providing a direct head-to-head benchmark.
- Broad Institute of MIT and Harvard: Cambridge-based biomedical and genomic research institute co-affiliated with Harvard and MIT. Closely comparable academic translational research engine; Wyss collaborated with Broad on ML-driven antibiotic discovery for drug-resistant gonorrhea.
- Mimetas: Dutch organ-on-chip company providing microfluidic 3D tissue models for drug discovery. Comparable to Wyss/Emulate on Organ Chip product category and pharma/biotech customer base, with strong presence in European pharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Wyss Institute social profiles
Digital presenceWyss Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wyss Institute leadership team
Management profileNumber of profiles
Profiles8 records
Wyss Institute subsidiaries and ownership
Company hierarchySubsidiaries7 records
Wyss Institute funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wyss Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wyss Institute
What does Wyss Institute do?
The Wyss Institute develops biologically inspired materials, devices, and platform technologies for healthcare and sustainability. Core offerings include Human Organs-on-Chips (microfluidic devices mimicking human organ function), the AI DataHub (AI-integrated biological data platform for drug discovery), the Diagnostics for Human and Planetary Health Platform, CRISPR-based diagnostics (dSHERLOCK), protein barcoding platforms, and RNA immunotherapeutics. Technologies are commercialized through licensing agreements, startup formation, and collaborative research with pharmaceutical companies and government agencies.
Is Wyss Institute a public or private company?
Wyss Institute is a private company. It is currently operating.
When was Wyss Institute founded?
Wyss Institute was founded in 2009. It employs 251 to 500 people.
Where is Wyss Institute based?
Wyss Institute is headquartered in Boston, United States, in the North America region.
How does Wyss Institute make money?
Four revenue lines are on record. Technology Licensing is the primary driver. The others are startup Formation, government Research Grants and collaborative Research Agreements.
Who are Wyss Institute's main competitors?
TissUse GmbH is listed as an emerging player. Broad incumbents are Gladstone Institutes, Koch Institute for Integrative Cancer Research (MIT) and Howard Hughes Medical Institute (HHMI). Direct peers are Emulate, Inc., Manifold Bio, Dyno Therapeutics, CN Bio, Broad Institute of MIT and Harvard and Mimetas.
Does Wyss Institute have an API?
No public API is recorded for Wyss Institute.
What industry is Wyss Institute in?
Wyss Institute's product category is Biomedical Research and Technology Licensing. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.